Peroxisome Dysfunction Validation in Parkinson's Disease

🧫 Experiment Protocol ClinicalParkinson's DiseaseDGAT1/GPX4/PLIN2humanproposed

# Peroxisome Dysfunction Validation in Parkinson's Disease ## Background and Rationale This clinical investigation tests the hypothesis that peroxisome dysfunction represents an upstream pathogenic driver in Parkinson's disease, contributing to oxidative stress, lipid metabolism disruption, and neuroinflammation. The study employs a multi-modal approach combining advanced metabolomics, proteomics, and functional cellular assays to characterize peroxisome-related biomarkers in PD patients. Participants undergo comprehensive phenotyping including plasma very-long-chain fatty acid analysis, peroxisome-derived metabolite profiling via LC-MS/MS, and assessment of catalase activity and plasmalogen levels. Skin fibroblasts from participants are analyzed for peroxisome morphology using immunofluorescence microscopy and functional capacity through β-oxidation assays. The research addresses a novel mechanistic pathway that could explain the metabolic dysfunction observed in PD and its connection to mitochondrial impairment. By establishing peroxisome dysfunction as a quantifiable biomarker, this study could identify patients who would benefit from peroxisome-targeted therapies such as bezafibrate or dietary interventions. The findings may reveal peroxisome function as a modifiable risk factor that precedes classical motor symptoms. This experiment directly tests predictions arising from the following hypotheses: - **Senescence-Induced Lipid Peroxidation Spreading** - **Metabolic Circuit Breaker via Lipid Droplet Modulation** - **Lipid Droplet Dynamics as Phenotype Switches** - **AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses** - **Digital Twin-Guided Metabolic Reprogramming** ## Experimental Protocol **Phase 1: Participant Recruitment and Baseline Assessment (Months 1-3)** • Recruit 150 PD patients (Hoehn & Yahr stages 1-3) from movement disorder clinics • Recruit 75 age-matched healthy controls • Obtain informed consent and perform comprehensive neurological evaluation • Collect medical history, medication records, and family history • Perform MDS-UPDRS Parts I-IV assessments • Collect baseline blood samples (50mL) and CSF samples (10mL) via lumbar puncture **Phase 2: Peroxisome Function Assessment (Months 2-4)** • Measure plasma very long-chain fatty acids (VLCFA) using GC-MS • Quantify pristanic and phytanic acid levels via LC-MS/MS • Assess bile acid synthesis intermediates (DHCA, THCA) in plasma • Evaluate catalase activity in peripheral blood mononuclear cells • Measure plasmalogen levels (16:0, 18:0, 18:1) in erythrocyte membranes • Quantify peroxisomal β-oxidation capacity using cultured skin fibroblasts **Phase 3: Alpha-Synuclein and Inflammatory Markers (Months 3-5)** • Measure CSF α-synuclein oligomers using RT-QuIC assay • Quantify phosphorylated α-synuclein (Ser129) via ELISA • Assess CSF inflammatory markers (IL-1β, TNF-α, IL-6) • Evaluate oxidative stress markers (8-OHdG, F2-isoprostanes) • Measure CSF neurofilament light chain as neurodegeneration marker **Phase 4: Imaging and Correlation Analysis (Months 4-6)** • Perform DaTscan SPECT imaging to assess dopaminergic function • Conduct brain MRI with DTI to evaluate white matter integrity • Correlate peroxisomal dysfunction markers with clinical severity scores • Statistical analysis using multivariate regression and machine learning approaches ## Expected Outcomes 1. **Elevated VLCFA levels**: PD patients will show 2-3 fold increase in C26:0/C22:0 ratio compared to controls (p<0.001) 2. **Reduced plasmalogen content**: 25-40% decrease in erythrocyte plasmalogen levels in PD patients versus controls 3. **Impaired peroxisomal β-oxidation**: 30-50% reduction in β-oxidation capacity in PD patient fibroblasts compared to controls 4. **Correlation with α-synuclein**: Strong positive correlation (r>0.6) between peroxisomal dysfunction markers and CSF α-synuclein oligomers 5. **Disease severity association**: Significant correlation (r>0.5) between peroxisomal markers and MDS-UPDRS motor scores 6. **Inflammatory pathway activation**: 2-4 fold elevation in pro-inflammatory cytokines correlating with peroxisomal dysfunction severity ## Success Criteria • **Primary endpoint achievement**: Statistically significant difference (p<0.001) in at least 3 peroxisomal function markers between PD patients and controls • **Effect size requirement**: Cohen's d ≥ 0.8 for primary peroxisomal dysfunction markers • **Correlation strength**: Pearson correlation coefficient r ≥ 0.5 between peroxisomal markers and clinical severity measures • **Sample size adequacy**: Completion of assessments in ≥80% of enrolled participants (≥120 PD patients, ≥60 controls) • **Biomarker validation**: AUC ≥ 0.80 for peroxisomal markers in discriminating PD from controls using ROC analysis • **Multi-marker panel performance**: Combined peroxisomal dysfunction score achieving sensitivity >85% and specificity >80% for PD diagnosis

Source: wiki

🧫 Experiment Extras

🟢 Parkinson's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found